Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry

May 16, 2012

Overview : Background Previous studies have demonstrated significant heterogeneity in responses to APT, and high residual platelet reactivity is associated with the risk of ischaemic events, including ST. Knowledge Gap The clinical impact of APT is unknown in the “real world’ setting Aim... more

Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease

May 02, 2012

Overview : Background Endothelial nitric oxide synthase (eNOS) plays an important role in maintenance of endothelial function and vascular homeostasis. Tetrahydrobiopterin is an essential cofactor for eNOS. Elevation of endogenous BH4 levels by oral BH4 treatment has been suggested as a possible... more

Prior antiplatelet or anticoagulant therapy and mortality in stroke

May 02, 2012

Overview : Background Today there is widespread use of antiplatelet or anticoagulant medication for the primary prevention of cardiovascular events. Bearing in mind the associated hemorrhagic side-effects of these medications, there are potentially harmful effects especially in patients experiencing a stroke. Knowledge... more

Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: nationwide cohort study.

May 02, 2012

Overview : Background Guidelines recommend discontinuation of hormone-replacement therapy (HRT) in women diagnosed with coronary artery disease. Discontinuation of HRT can be troublesome owing to the rebound of climacteric symptoms, as well as its theoretical favorable effects on endothelial function, inflammatory and... more

A randomized, 2-Period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers

May 02, 2012

Overview : Background The co-administration of proton pump inhibitors (PPI) with clopidogrel reduces the risk of gastrointestinal (GI) bleeding associated with the antiplatelet effects of clopidogrel. There are conflicting data as to whether PPIs have the potential to reduce the effectiveness of... more